Healthcare entity

Citadel Advisors LLC

Company

Of the tracked stories, 2 of 2 also mention Wall Street Zen, the most common co-covered peer. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each.

Last mentioned: Aug 13, 2026

Entity pulse

Recent coverage · Citadel Advisors LLC

2 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Citadel Advisors LLC

Of the tracked stories, 2 of 2 also mention Wall Street Zen, the most common co-covered peer. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. The tracked stories average 2 original sources each. Citadel Advisors LLC appears in 2 tracked Healthcare stories from August 13, 2026.

Stories tracked
2
Sources per story
2

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 18 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Citadel Advisors LLC. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Citadel Advisors LLC 2

Medical Devices Neutral

Renuvion Maker Apyx Drops 1.8% to $4.38 Despite Q1 Revenue Beat

For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.

2 sources
Market Trends Neutral

ENSC Shorts Up 619.9% at $0.30; FCUV Revenue $0.05M

Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.

2 sources

Citadel Advisors LLC is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.